Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1
• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1

Comparison of infection risk across b/tsDMARDs in IA in real-world study Treatment with ➡️Rituximab ➡️JAKi ➡️Anti-IL6 assoc with ⬆️⬆️ risk of severe infection compared to TNFi A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs Ab1716 #ACR24 @RheumNow

RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor. #ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO

• https://x.com/JihaRheum/status/1858256799196971041/photo/1

In this systematic review & metaanalyis by Dr. RFarhat et al, tacrolimus whole blood levels decrease in the 1st & 2nd trimesters then increase back to pre-pregnancy levels postpartum. Needs further studies to guide dose adjustment. @RheumNow #ACR24 abs1535 https://t.co/5MovzPJoFc

• https://x.com/RHEUMarampa/status/1858257864025833970/photo/1

Dr. BDinneen et al reported predictors that can help screen axSpA pts w/o traditional CV RFs for carotid doppler utz: - shorter dse duration - no family hx of IHD - HLAB27+ - ⬆️ dBP, WHratio, ferritin, TC, LDL and TC:HDL ratio Small size, more data reqd @RheumNow #ACR24 abs1440 https://t.co/3pZxFmutJz

• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1
• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1

Ab1676 discussed an intervention to change patient mindsets about side-effects of #methotrexate. Watch my video for @RheumNow on this abstract here: https://t.co/NxuxQ5wYda #ACR24

• Changing Mindsets about Methotrexate Side Effects

Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr

• Effectiveness and Safety of Tofacitinib vs. Calcineurin Inhibitor in Interstiti…
• https://x.com/RichardPAConway/status/1858261329993212326/photo/1

A#1747 RA mortality by race/ethnicity Database study >200,000 pts had RA as contributing cause of death 5.1 ASMR in American Indian >>> all other groups No decr over time in grp, unlike other grps Odds of death 1.67 compared to white pop 10.8x higher in pts <44 #ACR24 @RheumNow https://t.co/nXLcQkQPu4

• https://x.com/ericdeinmd/status/1858254655928852760/photo/1
• https://x.com/ericdeinmd/status/1858254655928852760/photo/1

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

• Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Rando…
• https://x.com/RichardPAConway/status/1858251010788991334/photo/1

RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi). Prioritize statins for heart health in RA! #ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d

• https://x.com/JihaRheum/status/1858252521044893744/photo/1
• https://x.com/JihaRheum/status/1858252521044893744/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1

A#1745 Post-hoc ORAL Surveillance - statin <1/4 on a statin, only 53% h/o ASCVD on statin Incr in LDL was less on Tofa pts on statin Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD If high risk on tofa, statin helps! @RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI

• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1
• https://x.com/ericdeinmd/status/1858249048085434638/photo/1

Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc

• Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a…
• https://x.com/RichardPAConway/status/1858248746078785887/photo/1

Further evidence for risk of #MACE with cumulative GC use in RA In a national cohort of pts with RA: ⬆️cumulative GC exposure associated with ⬆️odds of MACE, regardless of baseline MACE risk Ab1719 #ACR24 @RheumNow https://t.co/RmxokfBXYX

• https://x.com/DrMiniDey/status/1858243461356687493/photo/1